Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects.
about
IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesisPhase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.Synergistic apoptosis of CML cells by buthionine sulfoximine and hydroxychavicol correlates with activation of AIF and GSH-ROS-JNK-ERK-iNOS pathway.Current therapeutic strategies for acute myeloid leukaemia.Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesRegulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responsesTargeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutationsAdvances towards the design and development of personalized non-small-cell lung cancer drug therapy.Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.Tyrosine dephosphorylation is required for Bak activation in apoptosis.MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells.Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells.
P2860
Q24655426-845D704C-B2C2-4738-9E11-7A22F120472AQ27852623-6AF3B183-D3D2-46F9-988F-7EB345709303Q28546856-D5ED2629-F8CE-4A6F-9BDF-227320FC46C8Q33732534-4EBDCB75-32B0-4E07-A82C-49CED4B190E4Q34802502-132062DD-D02B-478C-9BFC-9C68238F0B9CQ34989086-EE860E5B-4943-4C36-B30D-7CE420D9521DQ36539598-4FD58CF3-9D2A-44D1-ABA4-4F37F058D97BQ36812355-5BEB1159-6FB7-44FB-8AAB-5B3F1C7F2690Q36901497-3728A5DA-EFA9-4A06-A8BB-93521D34E920Q37109225-C42EF43D-34C7-4E00-A818-89687363E7D3Q37269341-BDE9588C-9F37-4FC3-8588-CBA7D65C3013Q38148583-D79C0E46-BA3D-4DA4-8DBE-D0C89A5FFDD0Q39383689-C0DDCF27-80CF-4F57-B56F-59C78C1A89C2Q39642126-7C722411-D6C4-4999-B2BF-CCBAC63AD9F0Q39987172-E5650C47-21AD-48DD-BE4B-67C58C9A99F0Q40217567-02E3A6D9-0A86-4214-B00D-D286974BA4A2Q40400934-29A5FE9D-F36A-49A8-B503-FCDDBCCADF7CQ42142241-B808C70C-D4E2-494F-B48B-8CF9F4A7B363
P2860
Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Beyond single pathway inhibiti ...... rgistic anti-leukemic effects.
@ast
Beyond single pathway inhibiti ...... rgistic anti-leukemic effects.
@en
type
label
Beyond single pathway inhibiti ...... rgistic anti-leukemic effects.
@ast
Beyond single pathway inhibiti ...... rgistic anti-leukemic effects.
@en
prefLabel
Beyond single pathway inhibiti ...... rgistic anti-leukemic effects.
@ast
Beyond single pathway inhibiti ...... rgistic anti-leukemic effects.
@en
P2093
P356
P1476
Beyond single pathway inhibiti ...... rgistic anti-leukemic effects.
@en
P2093
Andreeff M
Kornblau SM
Petrucci MT
Precupanu CM
Ricciardi MR
P304
P356
10.2174/1381612054546842
P577
2005-01-01T00:00:00Z